Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-hour Sleep Wake Disorder

Vanda Pharmaceuticals Inc. – Non-24-hour Sleep Wake Disorder

Biomarkers for Circadian Timing Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents Breath Biomarkers for Sleep Loss and Circadian Timing Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)